A recent meeting of World Pharmacopoeias in Suzhou, China, attended by regional and national pharmacopoeias made progress towards the critical goal of setting globally unified principles for creating quality standards for pharmaceutical preparations and promoting greater collaboration between standard setting bodies of individual countries and regions.
The Chinese Food and Drug Authority (CFDA) and WHO have just signed a ‘cooperation plan’ at WHO headquarters. The plan sets out a comprehensive package of measures that China will undertake with WHO’s technical assistance, specifically to improve the quality of generic medicines, create a more science based and efficient review and approval system, reduce drug submission backlogs and promote transparency of operations.
With globalised markets and increasing cross-border trade, protecting patients from unsafe, substandard and dangerous medical products requires global action based on information sharing and collaboration between many actors involved in medicines oversight.
In response to the current crisis in the supply of antivenoms, WHO has decided to open up a prequalification scheme for these products. The first call to manufacturers will go out on 1 December 2015.
9 October 2015
WHO, WTO, WIPO trilateral symposium
WTO, Centre William Rappard, rue de Lausanne 154, Geneva
28 October 2015 from 09h30 to 18h00
9 October 2015
Health and trade are strongly interconnected, with varying effects on public health. While trade can expand the availability of health products, intensified trade liberalisation - through bilateral free trade agreements - confronts national health authorities with increased movement of health personnel; medical tourism; higher levels of intellectual property protection impacting medicines’ prices; and harmful food products.
2 September 2015
In line with open access policies, the timely sharing of information on clinical, epidemiologic and genetic features of emerging infectious diseases as well as information on experimental diagnostics, therapeutics and vaccines, is critical for actions during a rapid public health response.
1 September 2015
In some countries, there is a risk that substandard medicines will be registered by national regulatory authorities because of a lack of technical capacity and poor resourcing. It causes problems not just for the individual country, but for the surrounding region – porous borders mean substandard medicines originating in one poorly-regulated jurisdiction can enter another country if the regulatory system is not strong enough to detect it.